How a New Urgency Score Reforms Donor Heart Allocation

Transplant centers face severe organ shortages worldwide. Currently, one in five heart transplant candidates dies or leaves the waitlist without receiving an organ. Modern donor heart allocation requires precise risk prediction to prioritize candidates facing imminent mortality. A major study in JAMA introduces the US Candidate Risk Score (US-CRS). Consequently, this innovative metric may redefine medical urgency standards globally.

Limitations of Existing Donor Heart Allocation Systems

The current allocation framework uses a six-status classification system. However, this system relies heavily on specific therapeutic interventions rather than pure patient physiology. For example, clinicians list candidates in higher tiers by initiating mechanical circulatory support or inotropic infusions. This design unfortunately creates perverse incentives. Furthermore, it allows clinicians to game the listing process. Many stable candidates on aggressive devices therefore receive undue priority. Meanwhile, truly fragile patients deteriorate while awaiting a suitable graft. Therefore, transplant cardiologists have long demanded a strictly objective risk score.

How the US Candidate Risk Score Operates

Researchers analyzed more than 38,000 adult candidates listed between 2019 and 2025. Specifically, they constructed a marginal structural model to predict six-week waitlist mortality without transplantation. The refined model incorporates five objective laboratory values. These biomarkers include serum sodium, bilirubin, creatinine or glomerular filtration rate, albumin, and natriuretic peptides. Additionally, the algorithm assesses four therapeutic device categories. These devices comprise durable left ventricular assist devices, intra-aortic balloon pumps, microaxial flow pumps, and advanced mechanical support. Thus, the model captures real biological compromise instead of simple treatment choices.

Validation and Match-Run Simulation Outcomes

Investigators evaluated the score using rigorous held-out test data. In test cross-sections, the US-CRS demonstrated superior discrimination compared to the existing six-status framework. Specifically, it achieved a time-dependent area under the curve of 0.807 versus 0.693 for the status quo. Furthermore, simulated match runs across 45,530 donor hearts produced profound reordering. Under the new policy, 67% of transplant recipients moved down in ranking. Most importantly, observed six-week waitlist mortality for the top-ranked candidate jumped from 11.2% to 15.7%. Consequently, the new algorithm directs life-saving grafts to individuals who need them most.

Clinical Implications for Global Heart Failure Management

These findings offer critical insights for heart failure specialists around the world. Although designed for the American registry, the US-CRS highlights the power of combining objective biomarkers with mechanical support data. Indian transplant centers also navigate acute organ shortages and strict candidate prioritization. Therefore, adopting objective scoring frameworks could enhance transparency across transplant registries. Furthermore, clinicians can better identify ambulatory candidates who are secretly failing medical therapy. Ultimately, objective risk quantification optimizes organ equity and saves vulnerable lives.

Frequently Asked Questions

Q1: What is the primary advantage of the US-CRS over current allocation rules?

The US-CRS uses objective laboratory values alongside device data to predict six-week mortality accurately. In contrast, current frameworks rely on physician treatment choices that can distort true patient urgency.

Q2: Which laboratory biomarkers does the new risk score evaluate?

The score evaluates five key laboratory markers: serum sodium, bilirubin, kidney function, serum albumin, and natriuretic peptides. Together, these markers reflect multiorgan end-stage congestion and hypoperfusion.

Q3: How does this scoring system impact transplant candidate rank order?

In simulated match runs, the score moved 67% of previous recipients downward in allocation ranking. Consequently, it prioritized much sicker candidates with higher baseline waitlist mortality.

References

1. Lyden GR et al. Development and Validation of an Adult Medical Urgency Score for US Donor Heart Allocation. JAMA. 2026 Oct 12. doi: 10.1001/jama.2026.17403. PMID: 42862588.
2. Parker WF et al. Development and Validation of a Risk Score Predicting Death Without Transplant in Adult Heart Transplant Candidates. JAMA. 2024;331(8):666-674.
3. Wood M. New policy could save more lives by prioritizing heart transplant candidates based on medical urgency, not treatment choices. UChicago Medicine. 2026.